Mean platelet volume as a prognostic factor for venous thromboembolic disease

Abstract

Background: Mean platelet volume (MPV) is a risk factor for cardiovascular and inflammatory diseases. Aim: To evaluate the association between high MPV and 90-day mortality after an episode of venous thromboembolism (VTE). Material and Methods: Retrospective cohort of 594 patients with a median age of 73 years (58% women) with a first episode VTE, included in an institutional Thromboembolic Disease registry between 2014 and 2015. MPV values were obtained from the automated blood cell count measured at the moment of VTE diagnosis. Volumes ≥ 11 fL were classified as high. All patients were followed for 90 days to assess survival. Results: The main comorbidities were cancer in 221 patients (37%), sepsis in 172 (29%) and coronary artery disease in 107 (18%). Median MPV was 8 fl (8-9), brain natriuretic peptide 2,000 pg/ml (1,025-3,900) and troponin 40 pg/ml (19.5-75). Overall mortality was 20% (121/594) during the 90 days of follow-up. Thirty three deaths occurred within 7 days and 43 within the first month. The loss of patients from follow-up was 5% (28/594) at 90 days. Mortality among patients with high MP was 36% (23/63). The crude mortality hazard ratio (HR) for high MPV was 2.2 (95% confidence intervals (CI) 1.4-3.5).When adjusted for sepsis, oncological disease, heart disease, kidney failure and surgery, the mortality HR of high MPV was 2.4 (CI95% 1.5-3.9) in the VTE group, 2.3 (CI95% 1.5-4.4) in the deep venous thrombosis group, and 2.9 (CI95% 1.6-5.6) in the pulmonary embolism group. Conclusions: High MPV is an independent risk factor for mortality following an episode of VTE.

<p>Clinical Significance of Factor XIII Activity and Monocyte-Derived Microparticles in Cancer Patients</p>

“…Other reports suggest that MPV is associated with VTE risk and survival in cancer patients. [35][36][37] In the present study, we observed the high level of RDW-SD, MPV, sE-selectin, sVCAM-1, PAI-1, MCP-1 and sCD14 in cancer patients, although we could not recognize the significance of these markers in CAT. However, an interesting marker was MDMP, because MPs could associate with CAT.…”

“…Several biomarkers have been reported in terms of CAT predictions thus far. [34][35][36][37][38][39] Zöller et al 34 reported that RDW-SD is associated with long-term incidence of the first event of VTE among middle-aged subjects, although not necessarily cancer. Other reports suggest that MPV is associated with VTE risk and survival in cancer patients.…”

Diagnostic significance of complete blood count in cardiovascular patients; Samara State Medical University

“…Другое исследование продемонстрировало, что MPV является ФР неспровоцированной венозной тромбоэмболии, а это позволяет предположить, что MPV и активность тромбоцитов являются ФР для развития не только артериальных, но и венозных тромбозов [23]. В недавнем ретро-спективном исследовании Díaz J, et al установлено, что высокий уровень MPV (>11,0 фл) является независимым ФР смерти пациентов с венозными тромбоэмболиями [24]. Kostrubiec M, et al также сообщили, что повышенные уровни MPV (>10,9 фл) являются независимыми предикторами ранней смертности пациентов с острой легочной эмболией в течение 7 и 30 дней: ОШ =2,0 (95% ДИ 1,3-3,0), p<0,001 и ОШ =1,7 (95% ДИ 1,2-2,5), p<0,01, соответственно.…”

Platelets in aging and cancer—“double-edged sword”

“…Enhanced platelet activation as determined by mean platelet volume (MPV) is seen in cancer patients, and may correlate with tumor stage [122,123]. Both MPV and increased soluble P-selectin levels correlate with VTE development in cancer patients [124][125][126]. Age does not predict VTE risk for all cancer types, suggesting that at least for some cancer types, tumor cells themselves increase platelet reactivity and VTE risk [127].…”